A CD19 CAR-T cell therapy for leukaemia and lymphoma
Tisagenlecleucel
A one-off cell therapy that re-engineers a person's own immune cells to attack leukaemia or lymphoma.
What is Tisagenlecleucel?
Tisagenlecleucel is a specialist one-off cell therapy used for certain types of leukaemia (a blood cancer, particularly in younger people) and lymphoma. It is a CAR-T therapy: a person's own immune T cells are collected, changed in a laboratory to recognise a marker called CD19 on cancer cells, and given back as a single infusion so they hunt down and destroy the cancer. The two most important risks are cytokine release syndrome (a strong immune reaction) and serious neurological events such as confusion or difficulty speaking. Because of these, it is given only in certified centres with tocilizumab and emergency care immediately available. Prolonged low blood counts and serious infections are also important. It is usually given once.
Education and reference only. This is a plain-language guide to Tisagenlecleucel — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Tisagenlecleucel is a specialist cancer treatment known as CAR-T cell therapy, used for certain types of B-cell acute lymphoblastic leukaemia (a blood and bone-marrow cancer, especially in children and young adults) and some large B-cell lymphomas. It is made individually for each person: their own immune T cells are collected, sent to a laboratory and genetically changed so they carry a receptor that recognises a marker called CD19 on cancer cells. These modified cells are then grown and given back to the person as a single infusion (a drip) into a vein. It is given in specialist certified centres equipped to manage its serious side effects.
How it works
T cells are immune cells that can kill abnormal cells, but they often do not recognise cancer well. In tisagenlecleucel, a person's own T cells are taken and given a new receptor (a chimeric antigen receptor, or CAR) that locks onto CD19, a marker on B cells and on the B-cell cancers being treated. When the modified cells are returned to the body, they seek out and destroy CD19-bearing cancer cells, and they can keep multiplying to continue the attack. This powerful, living treatment is why it can work after other treatments have failed, but also why it can cause a strong immune reaction (cytokine release syndrome) and effects on the nervous system, usually in the first weeks.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist one-off cell therapy used in the UK in certified centres for some leukaemias and lymphomas.
Practical use
How to take Tisagenlecleucel
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a single, one-off infusion into a vein in a certified specialist centre, after your own cells are collected and modified.
- You stay close to the centre for a period afterwards so the team can watch for and treat side effects.
- Report fever, dizziness or breathing difficulty straight away, as these can signal cytokine release syndrome.
- You and those close to you should watch for confusion, difficulty speaking, drowsiness or tremor, and report them at once; do not drive for the period advised.
- Take the infection-prevention medicines you are given, report any high temperature urgently, and use reliable contraception as your team advises.
Weighing it up
Advantages & disadvantages of Tisagenlecleucel
Advantages
- A powerful, living treatment that can work in some leukaemias and lymphomas after other treatments fail.
- Usually given as a single, one-off infusion rather than ongoing treatment.
- Uses a person's own immune cells, re-engineered to seek out and destroy CD19-bearing cancer cells.
Disadvantages
- Can cause cytokine release syndrome, a strong immune reaction needing prompt treatment.
- Can cause serious neurological events such as confusion or difficulty speaking.
- Blood counts can stay low for a long time, raising the risk of serious infection and bleeding.
Practical use
Good to know
Because the modified cells multiply and attack strongly, the two effects to understand most are cytokine release syndrome and neurological events. Cytokine release syndrome is a strong immune reaction that can cause high fever, low blood pressure and breathing difficulty, usually in the first days to weeks; it is treated promptly, and the medicine tocilizumab must be immediately available, which is why treatment is only given in certified centres. Neurological events can include confusion, difficulty speaking, drowsiness, tremor or, rarely, seizures, so you and those around you are asked to watch for and report them, and you are usually advised not to drive for a period. Blood counts can stay low for a long time, raising the risk of infection and bleeding, and serious infections can occur, so infection-prevention medicines are used and any high temperature must be reported urgently. It also lowers normal B cells, so antibody (immunoglobulin) replacement may be needed. It is usually given as a single, one-off treatment, and it can harm a developing baby, so reliable contraception is advised.
Who should not take it / use with caution
- People who have had a serious allergic reaction to this therapy or its components should not receive it.
- It is not given during pregnancy because it can harm a developing baby.
- It is given only in certified centres to people assessed as suitable, with active serious infection or certain other conditions needing careful consideration first.
Monitoring
- Close monitoring in and near a certified centre for cytokine release syndrome and neurological events.
- Regular blood tests for blood counts and antibody levels, with infection monitoring over the long term.
- Ongoing review of recovery, side effects and how the cancer has responded.
Side effects
- Cytokine release syndrome, with high fever, low blood pressure and breathing difficulty.
- Neurological events such as confusion, difficulty speaking, drowsiness or tremor.
- Prolonged low blood counts, raising the risk of serious infection and bleeding.
- Serious infections and a long-term drop in normal antibodies, which may need replacement.
Key interactions
- Tell your team about all your medicines, as some affect the immune system or add to infection risk.
- Steroids and some immune-suppressing medicines are usually avoided around the time of treatment unless your team advises otherwise.
- Live vaccines are avoided before and for a period after treatment; check with your team before any vaccination.
Available as: A one-off infusion of modified cells given into a vein in a certified centre.
Answers
Tisagenlecleucel: frequently asked questions
What is tisagenlecleucel used for?
It is a CAR-T cell therapy used for certain B-cell leukaemias (especially in children and young adults) and some large B-cell lymphomas, after other treatments.
How is it different from other cancer treatments?
It uses your own immune T cells, changed in a laboratory to recognise the CD19 marker on cancer cells, given back as a single infusion so they attack the cancer.
Why must it be given in a certified centre?
It can cause cytokine release syndrome and serious neurological events, so it is given where the medicine tocilizumab and emergency care are immediately available.
How long do the side effects last?
Cytokine release syndrome and neurological effects mostly occur in the first weeks, but low blood counts and infection risk can last longer, so monitoring continues.
Is it a one-off treatment?
Yes, it is usually given as a single, one-off infusion, with close monitoring and follow-up afterwards to manage side effects and check the response.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.